A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

E
Erik Imel, MD

Primary Investigator

Overview

We are doing this research study because we are trying to learn more about a drug called Denosumab in children with glucocorticoid-induced osteoporosis.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Glucocorticoid-induced Osteoporosis
  • Age: Between 5 Years - 17 Years
  • Gender: All

Inclusion Criteria

Clinical diagnosis of GiOP

Other criteria exists-please contact study team

Updated on 20 Nov 2022. Study ID: 1809456517

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center